Cyclonex

Country: নিউ জিলণ্ড

ভাষা: ইংরেজি

সূত্র: Medsafe (Medicines Safety Authority)

সক্রিয় উপাদান:

Cyclophosphamide monohydrate 53.5mg equivalent to 50 mg cyclophosphamide

থেকে পাওয়া:

Boucher & Muir (NZ) Ltd t/a Mercury Pharma (NZ)

INN (International Name):

Cyclophosphamide monohydrate 53.5 mg

ডোজ:

50 mg

ফার্মাসিউটিকাল ফর্ম:

Film coated tablet

রচনা:

Active: Cyclophosphamide monohydrate 53.5mg equivalent to 50 mg cyclophosphamide Excipient: Croscarmellose sodium Isopropyl alcohol Lactose monohydrate Magnesium stearate Microcrystalline cellulose Opadry pink 21F240000 Purified water

প্যাকেজ ইউনিট:

Bottle, plastic, 40ml, 50 tablet pack, 50 tablets

শ্রেণী:

Prescription

প্রেসক্রিপশন টাইপ:

Prescription

Manufactured by:

Orion Corporation

থেরাপিউটিক ইঙ্গিত:

Cyclophosphamide is a cytotoxic drug for the treatment of malignant disease in adults and children. As a single agent, it has successfully produced an objective remission in a wide range of malignant conditions. Cyclophosphamide is also frequently used in combination with other cytotoxic drugs, radiotherapy or surgery

পণ্য সারাংশ:

Package - Contents - Shelf Life: Blister pack, Al/PA/Al/PVC - 50 tablets - 24 months from date of manufacture stored at or below 25°C protect from light

অনুমোদন তারিখ:

1985-08-15

পণ্য বৈশিষ্ট্য

1
CYCLONEX
CYCLOPHOSPHAMIDE TABLETS 50 MG
NEW ZEALAND DATA SHEET
1
PRODUCT NAME
CYCLONEX
50 mg film coated tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each
tablet
contains
cyclophosphamide
monohydrate
equivalent
to
50
mg
cyclophosphamide
EXCIPIENT(S) WITH KNOWN EFFECT:
sugars as lactose
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Film coated tablet
Brown to pinkish round convex film coated tablet.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Cyclophosphamide is a cytotoxic drug for the treatment of malignant
disease in adults
and children. As a single agent, it has successfully produced an
objective remission in a
wide range of malignant conditions. Cyclophosphamide is also
frequently used in
combination with other cytotoxic drugs, radiotherapy or surgery.
4.2
DOSE AND METHOD OF ADMINISTRATION
Cyclonex Tablets are for oral use.
Cyclophosphamide should only be used by clinicians experienced in the
use of cancer
chemotherapy.
Cyclophosphamide should only be administered where there are
facilities for regular
monitoring of clinical, biochemical and haematological parameters
before, during, and
after administration and under the direction of a specialist oncology
service.
2
CYCLONEX
CYCLOPHOSPHAMIDE TABLETS 50 MG
DOSE
Dosage must be individualized. Doses and duration of treatment and/or
treatment intervals
depend on the therapeutic indication, the scheme of a combination
therapy, the patient's
general state of health and organ function, and the results of
laboratory monitoring (in
particular, blood cell monitoring).
The dosage regimen used for most indications is 100 – 300 mg daily
as a single or divided
dose.
This treatment should be continued until a clear remission or
improvement is seen or be
interrupted when the extent of leucopenia becomes unacceptable.
In combination with other cytostatics of similar toxicity, a dose
reduction or extension of
the therapy-free intervals may be necessary.
Activation
of
cyclophosphamide
requires
hepatic
metabolism;
therefore,
oral
and
in